Jefferies has maintained a hold rating on Divi’s Laboratories with a target price of Rs 6,200, suggesting a modest downside of around 1% from the current market price of Rs 6,268.00.
The brokerage noted that Q4 performance was in line with expectations. Divi’s currently has multiple projects under development across GLP-1, GLP-2, GIP, and small molecule categories but is not pursuing the generic Semaglutide opportunity.
Jefferies cited near-term patent challenges and a high valuation — currently trading at 51x FY27 estimated earnings — as reasons for maintaining a cautious stance.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult certified financial professionals before making any investment decisions.
